作者: G. A. Ulaner , C. C. Riedl
DOI: 10.2967/JNUMED.115.161042
关键词:
摘要: REPLY: We thank Drs. Groheux and Hindie for their comments on our article ([1][1]). Their position ours are quite similar. both support the growing evidence using 18F-FDG PET/CT systemic staging of patients with newly diagnosed stage III or IIB breast cancer ([1][1],[2][2]), because